Analyst Report: BioNTech SE (BNTX) - Buy

Professional analyst consensus for BioNTech SE ($BNTX)

Analyst Consensus: • Rating: Buy

• Analysts Coverage: 12 analysts

• Price Target: $171.44

• Potential Upside: ↗️ 66.2%

Market Cap: 24.8B

Key Insights: HC Wainwright keeps a Buy and $140 target on BioNTech, citing 2025 revenue guidance rising to €2.6–2.8B, >90% R&D shift to non‑COVID oncology/mRNA, and a DCF valuation (8% discount, 2% terminal) valuing the firm at $35.3B, while noting regulatory and uptake risks. The report is bullish.

View detailed analysis on Stocknear

Compare analyst ratings